A 5-year longitudinal study of macular atrophy

Authors

  • Rosa Lomelino Pinheiro Ophthalmology Unit, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal
  • Dra. Ophthalmology Unit, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal
  • Maria da Luz Cachulo Ophthalmology Unit, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal; Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal; University Clinic of Ophthalmology, Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal
  • Mário Soares Ophthalmology Unit, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal
  • Pedro Melo Ophthalmology Unit, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal
  • Joaquim Murta Ophthalmology Unit, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal; Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal; University Clinic of Ophthalmology, Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal
  • Rufino Silva Ophthalmology Unit, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal; Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal; University Clinic of Ophthalmology, Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal

DOI:

https://doi.org/10.48560/rspo.25965

Keywords:

Aflibercept, Macula Lutea, Macular Degeneration/drug therapy, Ranibizumab

Abstract

Macular atrophy (MA) is one of the late stages of age-related macular degeneration (AMD) and leads to irreversible loss of visual function. During the past years, efforts have been made towards a more detailed comprehension of the characteristics of MA, and a panel of retina specialists has recently established a new classification system to describe atrophy in the context of neovascular AMD, by the CONAN group. Furthermore, recent publications have focused on investigating the progression of MA, as well as the factors that might influence MA growth rates, particularly anti-VEGF injections.

Downloads

Download data is not yet available.

References

Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, et al. Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology. 2018;125:537-48. doi:10.1016/j.ophtha.2017.09.028

Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G et al. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020;127:616-36. doi:10.1016/J.OPHTHA.2019.11.004

Spooner KL, Fraser-Bell S, Cozzi M, Staurenghi G, Invernizzi A, Monteduro D, et al. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study. Ophthalmology. 2020;127:1663-73. doi:10.1016/J.OPHTHA.2020.06.019

Abdelfattah NS, Al-Sheikh M, Pitetta S, Mousa A, Sadda SR, Wykoff CC; Treat-and-Extend Age-Related Macular Degeneration Study Group. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. Ophthalmology. 2017;124:215-23. doi:10.1016/J.OPHTHA.2016.10.002

Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Pecheur FL, et al. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study). Ophthalmology. 2020;127:198-210. doi:10.1016/J.OPHTHA.2019.08.023

Bailey C, Scott LJ, Rogers CA, Reeves BC, Hamill B, Peto T, et al. Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial. Ophthalmology. 2019;126:75-86. doi:10.1016/J.OPHTHA.2018.07.013

Siedlecki J, Fischer C, Schworm B, Kreutzer TC, Luft N, Kortuem KU, et al. Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under Treat & Extend Anti-Vascular Endothelial Growth Factor Inhibitors. Sci Rep. 2020;10. doi:10.1038/S41598-020-64901-9

Grunwald JE, Pistilli M, Daniel E, Ying GS, Pan W, Jaffe GJ, et al. Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2017;124:97-104. doi:10.1016/J.OPHTHA.2016.09.012

Berg K, Roald AB, Navaratnam J, Bragadóttir R. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration. Acta Ophthalmol. 2017;95:796-802. doi:10.1111/AOS.13522

Sadda SR, Abdelfattah NS, Lei J, Shi Y, Marion KM, Morgenthien E, et al. Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127:1360-70. doi:10.1016/J.OPHTHA.2020.03.031

Christenbury JG, Phasukkijwatana N, Gilani F, Freund KB, Sadda S, Sarraf D. Progression of macular atrophy in eyes with type 1 neovascularization and age-related macular degeneration receiving long-term intravitreal anti-vascular endothelial growth factor therapy: An optical coherence tomographic angiography analysis. Retina. 2018;38:1276-88. doi:10.1097/IAE.0000000000001766

Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol. 2004;137:496-503. doi:10.1016/J.AJO.2003.09.042

Cho HJ, Park SM, Kim J, Nah SK, Lee J, Lee DW, et al. Progression of macular atrophy in patients undergoing anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Acta Ophthalmol. 2021;99:e540-6. doi:10.1111/AOS.14631

Zarbin MA, Hill L, Maunz A, Gliem M, Stoilov I. Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy. Br J Ophthalmol. doi:10.1136/BJOPHTHALMOL-2020-318688

Jaffe GJ, Ying GS, Toth CA, Daniel E, Grunwald JE, Martin DF, et al. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2019;126:252-60. doi:10.1016/J.OPHTHA.2018.08.035

Koizumi H, Yamamoto A, Ogasawara M, Maruko I, Hasegawa T, Itagaki K, et al. Macular atrophy after aflibercept therapy for neovascular age-related macular degeneration: outcomes of Japanese multicenter study. Jpn J Ophthalmol. 2020;64:338-45. doi:10.1007/S10384-020-00745-0

Kuroda Y, Yamashiro K, Ooto S, Tamura H, Oishi A, Nakanishi H, et al. Macular atrophy and macular morphology in aflibercept-treated neovascular age-related macular degeneration. Retina. 2018;38:1743-50. doi:10.1097/IAE.0000000000001765

Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, et al. Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2013;120:1860-70. doi:10.1016/J.OPHTHA.2013.01.073

Eng VA, Rayess N, Nguyen H V, Leng T. Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration. PLoS One. 2020;15: :e0232353.doi:10.1371/JOURNAL.PONE.0232353

Mantel I, Dirani A, Zola M, Parvin P, De Massougnes S, Bergin C. Macular atrophy incidence in anti-vascular endothelial growth factor-treated neovascular age-related macular degeneration: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen. Retina. 2019;39:906-17. doi:10.1097/IAE.0000000000002054

Mantel I, Zola M, De Massougnes S, Dirani A, Bergin C. Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen. Br J Ophthalmol. 2019;103:900-5. doi:10.1136/BJOPHTHALMOL-2018-312430

Christakis PG, Agrón E, Klein ML, Clemons TE, Campbell JP, Ferris FL, et al. Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study Report 40. Ophthalmology. 2020;127:784-92. doi:10.1016/J.OPHTHA.2019.11.016

Gune S, Abdelfattah NS, Karamat A, Balasubramanian S, Marion KM, Morgenthien E, et al. Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127:523-32. doi:10.1016/J.OPHTHA.2019.09.030

Chakravarthy U. Does the Inhibition of Vacular Endothelial Growth Factor in Neovascular Age-Related Macular Degeneration Result in Macular Atrophy? Ophthalmology. 2020;127:533-4. doi:10.1016/J.OPHTHA.2020.01.016

Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292-9. doi:10.1016/J.OPHTHA.2013.03.046

Downloads

Published

2022-04-10

How to Cite

Pinheiro, R. L., Farinha, C., Cachulo, M. da L., Soares, M., Melo, P., Murta, J., & Silva, R. (2022). A 5-year longitudinal study of macular atrophy. Revista Sociedade Portuguesa De Oftalmologia, 46(1), 7–14. https://doi.org/10.48560/rspo.25965

Issue

Vol. 46 No. 1 (2022)

Section

Original Article

License

Copyright (c) 2022 Revista Sociedade Portuguesa de Oftalmologia

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Do not forget to download the Authorship responsibility statement/Authorization for Publication and Conflict of Interest.
The article can only be submitted with these two documents.
To obtain the Authorship responsibility statement/Authorization for Publication file, click here.

To obtain the Conflict of Interest file, click here

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.